Aquestive Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Warren Township NJ United States (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2008
NCT01217801
First Marketed Drug
2010
ondansetron (zofran)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

AQUESTIVE | AQUESTIVE THERAP | Aquestive Therapeutics | MonoSol Rx

Active Ingredients

Marketed Drugs (4)

clobazam (onfi) (2018)

diazepam (valium) (2022)

ondansetron (zofran) (2010)

riluzole (rilutek) (2019)

Drugs in Phase 3 Trials (1)

diazepam (valium) (4 trials)

Drugs in Phase 2 Trials (1)

riluzole (rilutek) (2 trials)

Drugs in Phase 1 Trials (1)

ondansetron (zofran) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Epilepsy (Phase 3)

Malnutrition (Phase 1)

Motor Neuron Disease (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 3